Universal Beteiligungs und Servicegesellschaft mbH Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 66,251 shares of the company’s stock, valued at approximately $4,131,000.

Other institutional investors have also recently made changes to their positions in the company. Mackenzie Financial Corp increased its holdings in TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after purchasing an additional 349,403 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in TransMedics Group in the 4th quarter valued at approximately $1,436,000. Pacific Point Advisors LLC acquired a new stake in TransMedics Group in the 4th quarter valued at approximately $561,000. Palisades Investment Partners LLC increased its holdings in TransMedics Group by 7.6% in the 4th quarter. Palisades Investment Partners LLC now owns 160,108 shares of the company’s stock valued at $9,983,000 after purchasing an additional 11,323 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in TransMedics Group by 16.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock valued at $56,307,000 after purchasing an additional 128,474 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Transactions at TransMedics Group

In related news, Director David Weill sold 732 shares of the business’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director now directly owns 12,134 shares of the company’s stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,000 shares of the business’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,732 shares of company stock valued at $1,416,710. Insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Oppenheimer lifted their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Friday, May 9th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $126.70.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $127.94 on Monday. The company has a fifty day simple moving average of $95.30 and a two-hundred day simple moving average of $78.49. The company has a market cap of $4.33 billion, a price-to-earnings ratio of 136.11 and a beta of 1.91. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 EPS. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.